Sarepta therapeutics announces research agreement with u.s. department of defense to evaluate multiple constructs from its proprietary rna platform as treatments for covid-19

Sarepta therapeutics announces research agreement with u.s. department of defense to evaluate multiple constructs from its proprietary rna platform as treatments for covid-19.sarepta - to jointly identify antisense ligonucleotides using co's pmo platform with activity against sars-cov-2 for potential covid-19 treatment.sarepta - to manufacture & provide to usamriid multiple peptide-conjugated pmo constructs based on genetic sequencing of sars-cov-2 for covid-19.sarepta therapeutics - based on results, co, usamriid to consider collaborative funding proposals to advance development of treatments for covid-19.sarepta therapeutics - usamriid to evaluate constructs on characterized wild-type sars-cov-2 viruses for potential to inhibit viral infection.
SRPT Ratings Summary
SRPT Quant Ranking